Reiner Z, Catapano AL, Backer AD et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2011, 32: 1769-1818.
Stone NJ, Robinson J, Lichtenstein AH at all 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
Jones P.H., Davidson M.H., Stein E.A. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.
Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med, 2004 April 8, 350: 15.
LaRosa JS, Grundy SM, Waters DD et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med, 2005, 352: 1425-35.
Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med, 359(21): 2195-207.
Amarenco P., Bogousslavsky J., Callahan A. 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006 Aug 10, 355(6): 549-59.
Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet, 2010, 376: 1916-1922
Diamond GA, Kaul S. Prevention and treatment: a tale of two strategies. J Am Coll Cardiol, 2008 Jan 1, 51(1): 46-8.
Flint AC, Kamel H, Navi BB et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke., 2012 Jan, 43(1): 147-54.
Jauch EC, Saver JL, Adams HP et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American. Stroke, 2013, 44: 870-947.
Cohen DE, Anania FA, Chalasani N et al. An assessment of statin safety by hepatologists. Am J Cardiol, 2006, 97: 77-81.
Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol, 2006, 97: 95-97.
Newman C, Tsai J, Szarek M et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol, 2006 Jan 1, 97(1): 61-7.
Armitage J. The safety of statins in clinical practice. Lancet, 2007 Nov 24, 370(9601): 1781-90.
Stroes ES, Thompson PD, Corsini A et al. Statinassociated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J, 2015 May 1, 36(17): 1012-22.
Rydén L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases. Eur Heart J, 2013 Oct, 34(39): 3035-87.
Ott BR, Daiello LA, Dahabreh IJ et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med, 2015 Mar, 30(3): 348- 58.
Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med, 2014, 11: 1626-1635.
Gandaglia G, Briganti A, Jackson G et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol, 2014 May, 65(5): 968-78.